37 results about "Hypericin" patented technology

The invention belongs to the technical field of medicines, and discloses application of hyperforin in preparation of a medicine for preventing or treating amyotrophic lateral sclerosis. The hyperforin can improve the survival rate of stable transfection cell lines of amyotrophic lateral sclerosis related cell models (SOD1G93A / TDP43M337V), and the hyperforin is prompted to play a protective role in the two cell models. After the hyperforin is given, the expression levels of HO-1 and Drp1 proteins in SOD1G93A cells are increased, which indicates that the hyperforin has certain antioxidant activity; and mitochondrial division in cells can be inhibited, so that cell apoptosis is inhibited and retarded, and a protection effect is achieved. Hypericin can help to improve the SOD1G93A cell morphology and promote synaptic generation, and it is prompted that hypericin has a positive effect on maintaining normal functions of cells. In conclusion, the hyperforin plays a protective role in an SOD1G93A cell model and a TDP43M337V cell model, and the mechanism of the hyperforin is possibly related to the antioxidant activity, the mitochondrial function improvement and the like of the hyperforin.

The invention discloses a self-assembled PROTAC nano material based on natural product mitochondria targeting, which is a nano particle prepared from mitochondria targeting molecules, a photosensitizer and PROTAC as raw materials through a nano precipitation method. The mitochondrial targeting molecule is berberine, the photosensitizer is hypericin, and the PROTAC is dBET57; the ratio of the amount of substance of the dBET57 to the amount of substance of the berberine is (1-10): (1-10), and the ratio of the amount of substance of the dBET57 to the amount of substance of the hypericin is (1-10): (1-10). The nano material can be used for blocking multiple energy metabolism pathways of tumor cells, including glycolysis and oxidative phosphorylation, meanwhile, mitochondria is damaged, ferroptosis is induced, and the anti-tumor capacity of pharmacodynamic molecules is improved; bRD4 in tumor cells and downstream carcinogenic protein c-Myc of the BRD4 can be efficiently degraded. The invention also discloses an application of the nano material in preparation of antitumor drugs.

The invention relates to the field of biological medicines, in particular to application of hypericin to preparation of a medicine for treating liver cancer. The invention provides application of hypericin in preparation of a medicine for treating liver cancer and a pharmaceutical composition containing the hypericin. The inventor finds that hypericin is used as a traditional Chinese medicine compound, in-vitro experiments prove that hypericin can inhibit liver cancer cell proliferation, inhibit liver cancer cell migration and induce liver cancer cell apoptosis, in-vivo experiments prove that hypericin can significantly inhibit liver tumor cell growth in mice, and it is indicated that hypericin can treat liver cancer. The traditional Chinese medicine composition can be used as a component in medicines for treating liver cancer.

The present invention relates to a kit of parts for an oral care implement, the kit of parts comprising a light emitting device and an oral composition, the oral composition comprising curcumin, curcuminoid, curcumin derivative or hypericin.

The present application relates to a kind of preparation method of Fugunkang composition and its detection method, the preparation method is cut into section, first using red koji and saccharomyces cerevisiae combined fermentation extraction, dregs is extracted with water before boiling, concentrate and extract the fermentation liquor and water, it is obtained.The metabolic function of microorganism is fully utilized, promote the release and absorption of effective components of traditional Chinese medicine in vivo, so as to improve the curative effect of traditional Chinese medicine, reduce the side effect of traditional Chinese medicine.The detection method includes spray agent in just bed, parsnip medicine thin layer identification and the content detection of rutin, hypericin;The thin layer identification can identify just bed and parsnip medicine under the same chromatographic condition, the content detection increases the content detection of hypericin on the basis of original, and the content of rutin and hypericin can be determined simultaneously, save the detection cost, ensure the quality of raw material and finished product.

The invention discloses application of hypericin in preparation of a product for treating calcified aortic valve diseases, and belongs to the technical field of biological medicines. The present invention screens 260 mitochondrial-related compounds approved by the American Food and Drug Administration (FDA) to identify potential therapeutic agents. We employ a high content cell imaging system to assess the effects of these compounds on the expression levels of PGC-1 [alpha] and Runx2, where hypericin shows the most significant increase in the PGC-1 [alpha] / Runx2 ratio. After 52-week-old mice are subjected to western diet and intraperitoneal injection of 2.5 mg / kg hypericin once every other day, compared with a normal saline intraperitoneal injection group, the calcification degree of the valves of the mice supplemented with the hypericin is remarkably reduced after 16 weeks.

The invention discloses a cathepsin B activated chemiluminescent nanoparticle. The cathepsin B activated chemiluminescent nanoparticle is prepared from cat B-C-550, hypericin and DSPE-mPEG2000 (Distearoyl Phosphate Polyethylene-mPEG (Polyethylene Glycol) 2000 in a self-assembly manner; the structure of the cat B-C-550 is as shown in a formula I in the specification. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of reagents or drugs for screening or diagnosing tumors. The invention discloses an application of cat B enzyme activated chemiluminescent nanoparticles in preparation of a cancer imaging reagent and / or a medicine for treating tumors. According to the invention, chemiluminescence imaging and in-situ cancer PDT treatment without external exciting light are realized. The cat B enzyme response type chemiluminescent nanoparticles are high in stability and can be effectively targeted and enriched at tumor focus parts.

The invention provides application of hypericin in preparation of a medicine for pathological scars, and relates to the technical field of biology. According to the application, hypericin is applied to preparation of the medicine for treating and / or preventing pathological scars of subjects. And / or preparing a drug for down-regulating at least one of type I collagen, type III collagen and phosphorylated SMAD2 protein of a subject; and / or down-regulating at least one of type I collagen, type III collagen and phosphorylated SMAD2 protein in the subject for non-diagnostic and therapeutic purposes. The application provides an effective component which is safe and reliable, has a definite curative effect, is easy to prepare and is used for treating and / or preventing dermatologic scars.

The application discloses application of an active ingredient hypericin in Hypericum perforatum in preparation of anti-migraine drugs, relates to the technical field of medicines, and identifies the active ingredient hypericin that can enter the brain from Hypericum perforatum extract, further combines BV2 cell in-vitro anti-inflammatory experiments, and analyzes blood rheology indexes of cerebral blood vessels and blood stasis changes after drug administration of rats, and confirms that the hypericin has good anti-migraine effect. The application provides definite experimental basis for the application of the active ingredient in anti-migraine drugs.

The present invention relates to a kit of parts for an oral care device, comprising a light-emitting element and an oral composition comprising curcumin, curcuminoids, curcumin derivatives, or hypericin.

The present invention provides a composition with whitening and anti-aging effects, a preparation method and application thereof, and belongs to the technical field of medicine or cosmetics. The composition comprises: cucurbitacin F, sutherlandin-5-trans-p-coumarate, quercetin, rutin, wogonin, trifoliol, quercetin-3-O-β-D-xyloside, scutellariae, hyperoside, cinchona sucretin Ib, kaempferol-3-furanarabinoside, arbutin and astragalus glycoside. The composition has significant whitening and anti-freckle effects, anti-aging effects, and is suitable for various skin types such as dry, oily, mixed and sensitive skin, and has high biological application value in the field of cosmetics and medicine.

The present invention concerns a method for preventing muscle injuries and / or fatigue in a subject comprising the step of simultaneously, separately, or sequentially administrating to a subject in need thereof an effective amount of i) at least 20-Hydroxyecdysone, ii) at least rosavin, iii) at least one Medium-chain triglycerides (MCTs) and unsaturated fatty acid enriched oil, and iv) optionally a pharmaceutically acceptable carrier.

The present invention discloses a SAMe, 5-HTP, and St. John's wort compound nutritional supplement for emotional support and joint care, comprising 15-25 parts of S-adenosylmethionine, 5-10 parts of 5-hydroxytryptophan, 3-8 parts of St. John's wort extract, 8-15 parts of sodium chondroitin sulfate, 2-5 parts of sodium hyaluronate, 0.5-1.2 parts of vitamin B6, 1-3 parts of vitamin E, 4-9 parts of phosphatidylserine, and pharmaceutical excipients. The weight ratio of S-adenosylmethionine to 5-hydroxytryptophan is 3:1-5:2, the weight ratio of St. John's wort extract to 5-hydroxytryptophan is 0.6:1-0.8:1, and the weight ratio of the joint-care agents to the total core active ingredients is 10:3-20:3. The hypericin content in the St. John's wort extract is not less than 3%. By optimizing the component ratios and utilizing synergistic functional excipients, the present invention achieves dual synergy in emotional support and joint care, with high product stability and excellent bioavailability.

The invention relates to a composite hydrogel dressing as well as a preparation method and application thereof, and relates to the technical field of medical wound dressings. The SF / SA-H hydrogel dressing is obtained by taking silk fibroin (SF) and sodium alginate (SA) as a mixed solvent, adding hyperoside, mixing, pouring at a constant temperature, curing and demolding, the dressing realizes dual synergistic effects of antibiosis and anti-inflammation, has the characteristics of easily available raw materials, convenience in production and high safety while meeting the curative effect of DFU wound treatment, and has a wide application prospect. Large-scale production and clinical transformation are easy to realize, and the method has a wide medical application prospect.

The present invention provides an application of hypericin in the preparation of a drug for pathological scars, which relates to the field of biotechnology. The application includes applying hypericin to the preparation of a drug for treating and / or preventing pathological scars in a subject; and / or, preparing a drug for down-regulating at least one of type I collagen, type III collagen and phosphorylated SMAD2 protein in a subject; and / or, down-regulating at least one of type I collagen, type III collagen and phosphorylated SMAD2 protein in a subject for non-diagnostic and therapeutic purposes. The application provides an effective ingredient of a safe, reliable, and easy-to-prepare drug for treating and / or preventing skin pathological scars with definite curative effects.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of tumor necrosis factor-alpha (TNF-α), decrease the CCL2, and decrease the interleukin-1 beta (IL-1β) responsible for low grade chronic inflammation.In some embodiments, the composition comprises: epicatechin present in an amount of about 0.25% to about 1% w / w of the composition; EGCG present in an amount of about 0.01% to about 0.1% w / w of the composition; lycopene present in an amount of about 1% to about 3% w / w of the composition; quercetin present in an amount of about 0.1% to about 1% w / w of the composition; luteolin present in an amount of about 0.1% to about 1% w / w of the composition; vitamin A present in an amount of about 1% to about 7.5% w / w of the composition; vitamin C present in an amount of about 40% to about 77% w / w of the composition; and vitamin E present in an amount of about 15% to about 40% w / w of the composition. Such compositions are useful for improving LGCI by decreasing TNF-α, CCL2, and IL-1β concentration.

The invention provides application of hypericin in preparation of a medicine for preventing or treating infection or diseases caused by Zika viruses, and further provides a medicine composition for preventing or treating infection or diseases caused by Zika viruses, and the medicine composition comprises effective dose of hypericin, at least one medicinal carrier and / or at least one medicinal auxiliary material. The hypericin is found to be capable of effectively inhibiting the Zika virus RNA replication effect and / or inhibiting the protein function (such as expression of envelope E protein) of the Zika virus for the first time, it is proved that the hypericin has the potential effect of preventing or treating infection or diseases caused by the Zika virus, and a new scheme is provided for preventing or treating the Zika virus. More potential use values of the hypericin can be explored, and a new direction is also provided for a scheme of anti-mosquito-borne virus drugs.

The invention provides an antithrombin III determination kit, and belongs to the technical field of in-vitro detection.The kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises thrombin, benzamidine hydrochloride, hypericin and a reaction regulator, the reaction regulator is glycine and at least one of potassium chloride, sodium chloride, potassium sulfate and ammonium sulfate, and the reagent R2 comprises a reagent R1 and a reagent R2. The reagent R2 comprises a chromophoric substrate. In the kit disclosed by the invention, instantaneous inhibition of benzamidine hydrochloride added into the reagent R1 on thrombin and long-acting stabilization of hypericin are complementary, so that the stability of the reagent can be effectively improved, and meanwhile, the kit has good accuracy and repeatability and a relatively wide linear range; a new idea is provided for solving the stability problem of an antithrombin III activity detection reagent based on a chromophoric substrate method.

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

The present invention discloses the use of hypericin in regulating plant flowering and podding, belonging to the technical field of plant growth regulators. When the concentration of hypericin is 1-5×10 ‑5 mg / L, especially when the concentration is 1×10 ‑3 -2×10 ‑4 mg / L and 2×10 ‑3 -1×10 ‑ 3 mg / L, it can effectively promote plant flowering and podding. The present invention discovers that hypericin can promote plant flowering and increase the podding rate of plants, mainly by regulating the degradation and synthesis of chlorophyll in plants, enhancing or weakening the photosynthesis of leaves, and regulating energy metabolism, thereby inhibiting or promoting plant flowering and controlling podding.

Aiming at the three technical bottlenecks of low separation efficiency, high product purity and high solvent toxicity in the existing hypericin extraction and purification process, the mass transfer efficiency is improved through a steam explosion directional wall breaking technology, and the release efficiency of intracellular active ingredients is improved through multienzyme-ultrasonic coupling; multistage countercurrent chromatography separation is adopted to break through the selective limitation of traditional column chromatography on naphthdianthrone components, and the hypericin with the purity larger than or equal to 98% is finally obtained. The steam explosion technology is adopted, the dissolution rate of hypericin and other effective components is greatly increased, meanwhile, the extraction rate is increased, the yield is increased, and the cost is saved. According to the method, multienzyme-ultrasonic coupling and counter-current chromatography are combined, the problems of high energy consumption, high pollution and the like caused by strong acid (alkali) in a traditional plant extraction technology are integrally solved, oxidative deterioration caused by long-time heating of active ingredients is improved, meanwhile, the product purity is remarkably improved, and the method is suitable for industrial production. And a technical support is provided for construction of extraction production of clean, stable and high-quality natural products.

The invention relates to the technical field of radioactive degradable nano materials with tracing and treatment effects, in particular to a radioactive degradable nano material for tracing and treating tumors and a preparation method of the radioactive degradable nano material. The invention provides a radioactive degradable nano-material for tracing and treating tumors, the radioactive degradable nano-material has a shell-core structure, the radioactive degradable nano-material comprises an amphiphilic polymer and radioactive element-labeled hypericin, and the amphiphilic polymer wraps the radioactive element-labeled hypericin. According to the degradable nano material, the water solubility of the hypericin can be improved, the photosensitive stability of the hypericin is enhanced, and triple functions of targeted necrosis, brachytherapy and tracing imaging are realized.

The invention belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, and particularly relates to an I-type and II-type immunogen cell death inducer ion pairing engineering nano assembly and construction and application thereof. The nano assembly is formed by pairing an I-type ICD inducer, an II-type ICD inducer, hydrophobic auxiliary counter ions and amphiphilic lipid ions; the I-type ICD inducer is selected from mitoxantrone, adriamycin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; the hydrophobic auxiliary counter ions are selected from sodium cholesterol sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivatives, oleanolic acid and ursolic acid. The I-type ICD inducer and the II-type ICD inducer are combined for use, and the synergistic tumor treatment effect is achieved.

The present invention relates to a composition comprising a mixture of molecules, said mixture comprising at least chrysin, pinocembrin and CAPE, for its use in the prevention or treatment of neuroinflammation and / or diseases or disorders associated with neuroinflammation.

The invention provides a method for preparing hypericin nanoparticles by using a surfactant Span20, which comprises the following steps: 1) mixing Span20 and ultrapure water according to a solid-liquid ratio of 1 mg: 1-5 ml, and centrifuging to obtain a Span20 aqueous solution; and 2) mixing the hypericin and the Span20 aqueous solution according to a solid-liquid ratio of (5-8) mg: 1 ml, and carrying out vortex, centrifugation, ultrasonic disruption and freeze drying to obtain the hypericin nanoparticles. The invention also provides the hypericin nano ion prepared by the preparation method disclosed by the invention. The hypericin nano particles prepared by the preparation method disclosed by the invention are high in water solubility and high in drug bioavailability.

This invention belongs to the field of preservation technology, and specifically relates to a method for preparing an emulsion co-encapsulating hypericin and Sichuan pepper oil, and its application in chili pepper preservation. This invention solves the technical problems of low water solubility and poor bioavailability of hypericin alone, and high volatility and poor stability of Sichuan pepper oil alone, making it difficult to achieve long-lasting antibacterial effects, and the fact that the two have never been used in synergistic antibacterial applications. This invention uses Tween 80 as an emulsifier, dissolving it in deionized water to obtain an aqueous phase containing Tween 80; Sichuan pepper oil and Tween 80 are ultrasonically mixed, and hypericin is added and ultrasonically mixed to obtain an oil phase; the oil phase is then added dropwise to the aqueous phase and stirred, and homogenized using a high-speed homogenizer to obtain a crude emulsion; the crude emulsion is then treated in an ultrasonic cell disruptor to obtain a hypericin-Sichuan pepper oil nanoemulsion containing 5%~7% of both Tween 80 and Sichuan pepper oil by volume. The emulsion exhibits excellent stability, effectively inhibiting pathogens, delaying fruit and vegetable spoilage, and improving preservation effects.

The invention belongs to the technical field of biological medicines, and provides a method for detecting semen cuscutae-fructus lycii pharmacodynamic substances in blood plasma, which can be used for simultaneously and quantitatively detecting six semen cuscutae-fructus lycii pharmacodynamic substances (hyperoside, astragalus smicus glycoside, isoquercitrin, quercetin, kaempferol and betaine) in rat blood plasma. And further performing pharmacodynamic analysis on hormone levels (E2, FSH, LH and AMH) in PO I rat serum, constructing a drug-time-effect curve, and performing PK-PD correlation analysis. The method provided by the invention not only can efficiently, accurately and quantitatively analyze pharmacodynamic substances, but also can provide comprehensive pharmacokinetic and pharmacodynamic data support for clinical treatment of PO I, thereby providing a scientific basis for optimization and application of related drugs.

The invention relates to the technical field of treatment of neurodegenerative diseases, in particular to application of a Gpnmb gene in related tau protein diseases. The invention relates to a pharmaceutical composition, which comprises a small molecule compound capable of activating a v-ATP enzyme subunit ATP6V0D1 and / or ATP6V0D2, and is used for recovering lysosomal acidification and tau protein degradation capability of Gpnmb-deficient microglial cells, the small molecule compound is hypericin, and the pharmaceutical composition is used for treating neurodegenerative diseases related to tau protein accumulation. The application of the Gpnmb gene in related tau protein lesions reveals that deletion of the Gpnmb gene can aggravate pathological changes, neurodegenerative lesions and cognitive impairment of tau protein, clarifies the key effect of the Gpnmb gene in neuroprotection, and explains that Gpnmb regulates assembling of a v-ATP enzyme subunit ATP6V0D1 / D2 and maintains lysosomal acidification so as to promote degradation of the tau protein from the molecular level, so that the application of the Gpnmb gene in the related tau protein lesions is realized, and the application of the Gpnmb gene in the related tau protein lesions is realized. And a new target spot is provided for treatment.

The invention provides a novel preparation method and application of hyperforin. According to the invention, all metabolism genes in the biosynthesis process of hypericin are analyzed for the first time in the field. The analysis process is pioneering work and comprises discovery of the gene and the enzyme coded by the gene, functional demonstration and analysis of the hyperforin produced by using yeast and tobacco as biological chassis. The invention lays a foundation for industrial production of the hypericin and the intermediate thereof.